Two Sigma Advisers
ALGS icon

Two Sigma Advisers’s Aligos Therapeutics ALGS Stock Holding History

Two Sigma Advisers’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,000
Closed -$121K – 82
2025
Q4 		$121K Buy
+13,000
New +$123K ﹤0.01% 2199
2023
Q3 		– Sell
-2,096
Closed -$50.9K – 2374
2023
Q2 		$50.9K Sell
2,096
-1,032
-33% -$27.7K ﹤0.01% 2274
2023
Q1 		$68.3K Sell
3,128
-172
-5% -$6.57K ﹤0.01% 2421
2022
Q4 		$78.6K Sell
3,300
-1,400
-30% -$35.3K ﹤0.01% 2323
2022
Q3 		$129K Buy
4,700
+212
+5% +$7.04K ﹤0.01% 2274
2022
Q2 		$136K Buy
4,488
+1,980
+79% +$67.3K ﹤0.01% 2353
2022
Q1 		$135K Buy
2,508
+1,876
+297% +$150K ﹤0.01% 2449
2021
Q4 		$188K Sell
632
-28
-4% -$10.2K ﹤0.01% 2300
2021
Q3 		$256K Buy
+660
New +$261K ﹤0.01% 2175

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Two Sigma Advisers's ALGS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 13,000 shares — an estimated $121K sold.

Two Sigma Advisers first reported a position in ALGS in Q3 2021 and held it in 9 quarters. The position peaked at $256K in Q3 2021. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 13,000 Aligos Therapeutics shares in Q1 2026, an estimated $121K.
  • Two Sigma Advisers first reported a position in Aligos Therapeutics in Q3 2021 and held it in 9 quarters.
  • Two Sigma Advisers's Aligos Therapeutics position peaked at $256K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.